Guidant to distribute Thoratec's Vectra:
This article was originally published in Clinica
Guidant is to gain exclusive worldwide distribution rights to Thoratec's Vectra vascular access graft for a total of $3.5 million. Guidant has also issued Thoratec a four-year, unsecured credit line of $10 million. The product, which is approved for sale in Europe, provides access to the blood stream for dialysis patients. Thoratec has begun clinical trials for the product in the US. Guidant says Vectra complements its own products for the treatment of abdominal aortic aneurysms.
You may also be interested in...
Tensions between industry and the European Commission on the issue of health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future.
Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.
The German Bundestag has adopted the Unified Patent Court’s draft ratification bill with the necessary qualified majority.